Proteinuria as a Surrogate in Kidney Disease In primary GN membranous nephropathy and focal and segmental glomerulosclerosis assocciated with the nephrotic.

Slides:



Advertisements
Similar presentations
IDEAL 1 and IDEAL 2.
Advertisements

The PREVEND Study: Screening for micro-albuminuria
Renal Protection for Coronary Angiography in Advanced Renal Failure Patients by Prophylactic Hemodialysis Presented by Mike Touchy, HO-I.
Everolimus plus Reduced-Exposure CsA is as Effi cacious as Mycophenolic Acid plus Standard-Exposure CsA Reference: Silva Jr HT, Cibrik D, Johnston T, et.
Slides courtesy of Matt Hall Nottingham University Hospitals February 2011 Slides courtesy of Matt Hall Nottingham University Hospitals February 2011 Slides.
National Institute for Health and Clinical Excellence.
ISKDC. Primary nephrotic syndrome in children: Clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity.
Role of recurrent disease for late allograft loss Fernando G. Cosio Mayo Clinic, Rochester MN 10 th Banff conference on allograft pathology.
Proteinuria Outcome Lupus Nephritis Classes of Lupus Nephritis I.Minimal II.Mesangial III.Focal proliferative* IV.Diffuse proliferative* V.Membranous**
Women and Alport Syndrome Michelle Rheault, M.D. Assistant Professor Division of Pediatric Nephrology University of Minnesota, USA.
Case Presentation Dr Mohan Shenoy Consultant Paediatric Nephrologist Royal Manchester Children’s Hospital.
Case D 1 Age 37 M HIV for 17 years 1 week history of diarrhoea and fever Abrupt onset of oedema and oliguria Homosexual Teenage drug abuse.
R Bhimma Department of Paediatrics and Child Health
dcss. cs. amedd. army. mil/field/FLIP%20Disk%2041/FLIP
Sum Scores and Scores of Individual Components in Clinical Practice and Clinical Trials Lillian W. Gaber University of Tennessee.
1 Organisation and Practice of a Kidney Biopsy Register Firenze, 07 September 2009 Cataldo Abaterusso MD, PhD Division of Nephrology University of Verona.
8th Banff Conference on Allograft PathologyEdmonton, July 2005 Proteinuria with sirolimus therapy. Christophe Legendre Hôpital Necker, Université.
Lupus Nephritis in Children Renal involvement in SLE: 30% - 70% Renal involvement in SLE: 30% - 70% Most diagnosis in adolescence, rare < 5y/o Most diagnosis.
Feast or Famine: Survival and Chronic Kidney Disease Kerin Worley and Deb Gipson UNC Chapel Hill April, 2004.
Proteinuria as a Surrogate Outcome in IgA Nephropathy Ron Hogg MD Scott & White Medical Center Temple, Texas.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
Recurrent And De Novo GN After Renal Transplantation
A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.
Section 4: Managing progression of CKD. Glomerulosclerosis Reduction in number of functioning glomeruli Increased blood flow to remaining nephrons Intraglomerular.
1 Hepatitis B Treatment Dr R.V.S.N.Sarma., M.D., Consultant Physician & Chest Specialist.
RENAL DISEASE IN DIABETES
Diabetic Nephropathy Yiming Lit, M.D. May 5, 2009.
6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
Primary glomerular diseases Talia Weinstein MD PhD Sourasky Medical Center.
Effectiveness of combination Prednisone–Tacrolimus compared with Prednisone –Cyclosporine in treatment Steroid-Resistant Nephrotic Syndrome Dra. Irma Esther.
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
Severe vascular lesions and poor functional outcome
Nephrotic Syndrome Etiology Idiopathic nephrotic syndrome (90%)
Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Albuminuria; a tool for measuring non-blood pressure.
Dr M Sivalingam Renal Unit, Lister Hospital, Stevenage.
Case Report and Lit Review: Reduction of Proteinuria in Diabetic Nephropathy with Spironolactone Harry W. Floyd, M.D. Family Medicine Kingstree, South.
Alternating Courses of CHOP and DHAP Plus Rituximab (R) Followed by a High-Dose Cytarabine Regimen and ASCT is Superior to Six Courses of CHOP Plus R Followed.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
Implications of MDRD for Validity of Proteinuria as a Surrogate Endpoint.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
Time to Secondary Resistance (TSR) After Interruption of Imatinib: Updated Results of the Prospective French Sarcoma Group Randomized Phase III Trial on.
PROTEINURIA DR HEDAYATI. INTRODUCTION  URINARY PROTEIN > 150mg/day  More than 1 time  ↑ capillary permeability.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
TM RAPAMUNE ® O-1 RAPAMUNE ® Overview John F. Neylan, MD Vice President, Transplantation Immunology Clinical Research and Development Wyeth-Ayerst Research.
Glomerular diseases typical case reports morphology Doc. MUDr. Zdeňka Vernerová, CSc., MUDr. Martin Havrda.
Trial profile Mann JF et al. Lancet 2008;372:
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease S Bianchi, R Bigazzi and VM Campese Kidney.
The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
“Monitoring Systemic Lupus Erythematosus” Andres Quiceno, MD Presbyterian Hospital of Dallas.
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
Nephrology Journal Club The SPRINT Trial Parker Gregg
Section 4: Managing progression of CKD
Figure 1 Schematic representation of idiopathic nephrotic syndrome,
Effects of Uric acid- lowering therapy on renal outcomes: a systematic review and meta-analysis Nephrol Dial Transplant (2014) 29: Vaughan Washco.
Lupus Nephritis Treatment
“Systemic Lupus Erythematosus” Renal features
Treatment of primary FSGS
Idiopathic Membranous Glomerulopathy: Diagnosis and Treatment
Goede V et al. Proc ASH 2014;Abstract 3327.
Figure 5 Comparison of outcomes with belimumab or rituximab therapy
Nephrotic syndrome: What’s new, what’s not?
Volume 85, Issue 3, Pages (March 2014)
Volume 67, Pages S48-S51 (January 2005)
Volume 72, Issue 12, Pages (December 2007)
World Kidney Day 2016: Kidney Disease & Children
Response to cyclosporin A (CsA) treatment and renal outcome in patients with either nongenetic or genetic disease. Response to cyclosporin A (CsA) treatment.
Peggy W. G. du Buf-Vereijken, MD, Amanda J. W. Branten, MD, Jack F. M
Avasare et al. Am J Nephrol 2017;45:99-106  (DOI: / )
Presentation transcript:

Proteinuria as a Surrogate in Kidney Disease In primary GN membranous nephropathy and focal and segmental glomerulosclerosis assocciated with the nephrotic syndrome Daniel Cattran M.D.

Can we quantitate the “benefits” Observational studies Prospective gathered information Timed urine collection (24 hrs) On review used protein /creatinine ratios to substantiate values and changes Relationship to outcome (RCT)

Time to event Proteinuria Complete remission < 0.3 g/d and normal creatinine Partial remission g/d and 50% reduction from peak proteinuria and stable creatinine Progression Kidney survival Doubling baseline creatinine Rate of progression(slope of cr cl )

i pp=12g/d, delta crcl (mls/mo) = –3, crcl i= 96 X = (0.3 x 12) + (-0.3 x -3) + (-0.05 x 96) e x = 2.6 p = 2.6 / 3.6= 72% Cattran…KI 1995 Predicting likelihood of developing CKD in MGN

Currently only validation tool that has undergone model fitting and independent data set validation Toronto Finland Italy Chronic renal insufficiency47/184(26%) 13/78(17%) 25/101(25%) Sensitivity Proteinuria >3,5 g/d 93% 100% 84% Model 89% 77% 60% Specificity Proteinuria >3.5 g/day 38% 30% 17% Model 86% 89% 92% Positive predictive value Proteinuria >3.5 g/day 34% 24% 25% Model 67% 59% 64% Negative predictive value Proteinuria >3.5 g/day 94% 100% 76% Model 94% 95% 82% Accuracy 52% 43% 34% Model 85%87% 79% Cattran…KI 1997

MGN Effect of long-term proteinuria reduction on rate of progression Troyanov …Cattran KI 2004

No remission vs Partial Remission vs Complete Remission Changes odds re:ESRD from 1in 2 to 1in 10 with PR to none with CR at 10 years 90% 50% 100% Troyanov …Cattran KI 2004 (PR = 50% in proteinuria and <3.5g/d On Renal Survival

Value of proteinuria reduction in MGN

Data to support relationship between proteinuria reduction and long term outcome

IV MP 1gx3 + Pred 0.5mg/kg od alternating monthly with cyclophosamide 2.5 mg/kg over 6/12 Improves with cytotoxic/steroid therapy RCT’S MGN

Repeat RCT Cytotoxic plus Prednisone Jha Vet al JASN:18:2007

Cytotoxic plus Prednisone Effect on proteinuria CR and /or PR Treated vs Control

Jha Vet al JASN:18:2007 Effect on outcome Renal survival of decrease in proteinuria but delayed as expected Treated 90% Control 65%

Jha Vet al JASN:18:2007 And eGFR was improved (but >50% control treated later in study so likely blunted treatment effect) 20mls/min And effect on progression rate(eGFR)

Cattran et al K. I., 2001 Other therapy similar results RCT CNI’S CSA 3- 4mg/kg Nephrotic syndrome (MGN)improved with 6 mos CSA 3- 4mg/kg + 10 mg prednisone od x 6/12 (Cattran …KI 2001 )

More prolonged CNI Treatment of IMN I) Initial TREATMENT GROUPS CsA +Pred(0.6mg/kg w taper) 26pts (11 CR, 15 PR) CsA alone(2-3 mg/kg ) 17 pts (4 CR, 13 PR) II) TREATMENT REGIMEN beyond 12mos Pred tapered to ~0.1 mg/kg BW CsA tapered to ~1.5 mg/kg BW over 2 months F/U 22+/-16 mos Alexopoulos et al, Nephrol Dial Transplant 21(11):3127,2006 Alexopoulos et al, Nephrol Dial Transplant 21(11):3127,2006

RCT Tacrolimus monotherapy in Nephrotic MGN Praga et al KI 71:2007 Alternate CNI

Praga et al KI 71:2007 Effect of 12 months tacrolimus monotherapy on protinuria in MGN

Praga et al KI 71:2007 Effect on slowing progression(50 % change in creatinine) Tac 5%versus control 25% 25% 5%

Primary FSGS - NATURAL HISTORY COURSE COURSE n Spontaneous complete remission % n Rapidly progressive renal failure % n Slowly progressive renal % n Slowly progressive renal failure % n Persistent proteinuria %

Baseline characteristics 281 nephrotic FSGS Troyonov…Cattran JASN 2005

Effect of proteinuria reduction on rate of progression (slope of Cr Cl)

Effect of proteinuria reduction on survival (from ESRD)

FSGS Renal survival related to proteinuria remission: complete, partial and no remission 4 CR PR NR 100% 80% 40%

Data to support relationship between proteinuria reduction and long term outcome

All Obsevational

Cyclosporine vs Placebo in Steroid Resistant FSGS % REMISSION RCT 6 Mos Rx CNI vs Placebo) Effect on proteinuria

Placebo (n) Cyclosporine (n) Placebo Cyclosporine p<0.05 CNI vs Placebo in Steroid Resistant FSGS Effect on Cr Cl